An Australian-developed therapy aimed at halting motor neurone disease progression and restoring function will advance to a national Phase 2 clinical trial.
NuNerve, a company formed to commercialise research from UQ’s Queensland Brain Institute, has produced successful results in a human clinical trial for potential new treatment for MND.
Emeritus Professor Perry Bartlett and Dr Daniel Blackmore from UQ’s Queensland Brain Institute led a longitudinal study to find that high-intensity interval exercise improves brain function in older adults for up to 5 years.
Researchers have discovered an exercise ‘sweet spot’ that reverses the cognitive decline in ageing mice, paving the way for human studies in this area.